Sight Sciences, Inc. (NASDAQ:SGHT) Shares Bought by Barclays PLC

Barclays PLC increased its position in Sight Sciences, Inc. (NASDAQ:SGHT) by 317.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,300 shares of the company’s stock after buying an additional 38,248 shares during the period. Barclays PLC owned about 0.10% of Sight Sciences worth $317,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Geode Capital Management LLC raised its holdings in Sight Sciences by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 784,129 shares of the company’s stock valued at $4,941,000 after acquiring an additional 12,709 shares during the last quarter. Millrace Asset Group Inc. acquired a new position in Sight Sciences in the third quarter valued at $874,000. State Street Corp lifted its position in Sight Sciences by 17.4% during the third quarter. State Street Corp now owns 646,776 shares of the company’s stock worth $4,075,000 after buying an additional 95,843 shares during the period. Long Focus Capital Management LLC boosted its stake in Sight Sciences by 86.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 560,594 shares of the company’s stock worth $3,739,000 after buying an additional 260,594 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its holdings in Sight Sciences by 46.3% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 207,893 shares of the company’s stock valued at $1,310,000 after buying an additional 65,767 shares during the period. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Sight Sciences Stock Down 0.4 %

Shares of Sight Sciences stock opened at $2.83 on Monday. Sight Sciences, Inc. has a twelve month low of $2.67 and a twelve month high of $8.45. The stock has a market cap of $143.65 million, a price-to-earnings ratio of -2.77 and a beta of 2.57. The company has a current ratio of 10.18, a quick ratio of 9.74 and a debt-to-equity ratio of 0.36. The company has a fifty day moving average price of $3.65 and a 200 day moving average price of $5.40.

Sight Sciences (NASDAQ:SGHT) last issued its earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. The company had revenue of $20.16 million during the quarter, compared to the consensus estimate of $20.41 million. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. Equities research analysts forecast that Sight Sciences, Inc. will post -1.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on SGHT shares. Piper Sandler reissued a “neutral” rating and issued a $5.50 target price (down from $6.00) on shares of Sight Sciences in a research report on Friday, November 8th. Needham & Company LLC reiterated a “hold” rating on shares of Sight Sciences in a report on Tuesday, January 14th. Citigroup dropped their price objective on Sight Sciences from $5.80 to $4.60 and set a “neutral” rating for the company in a report on Wednesday, December 11th. Lake Street Capital reduced their target price on Sight Sciences from $5.00 to $3.00 and set a “hold” rating on the stock in a report on Wednesday, January 15th. Finally, Morgan Stanley dropped their price target on Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a research note on Monday, November 11th. Five investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $4.72.

Insider Activity

In related news, CEO Paul Badawi sold 12,236 shares of the firm’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $3.60, for a total transaction of $44,049.60. Following the completion of the sale, the chief executive officer now directly owns 5,713,197 shares of the company’s stock, valued at approximately $20,567,509.20. This trade represents a 0.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last 90 days, insiders have bought 15,000 shares of company stock worth $58,232 and have sold 25,850 shares worth $90,505. Insiders own 28.90% of the company’s stock.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.